Inspire Medical Systems, Inc. v. Nyxoah, Inc. and Nyxoah SA

CourtDistrict Court, D. Delaware
DecidedNovember 18, 2025
Docket1:25-cv-00667
StatusUnknown

This text of Inspire Medical Systems, Inc. v. Nyxoah, Inc. and Nyxoah SA (Inspire Medical Systems, Inc. v. Nyxoah, Inc. and Nyxoah SA) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Inspire Medical Systems, Inc. v. Nyxoah, Inc. and Nyxoah SA, (D. Del. 2025).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE INSPIRE MEDICAL SYSTEMS, INC., ) Plaintiff, v. C.A. No. 25-667-RGA NYXOAH, INC. and NYXOAH SA, Defendants. MEMORANDUM ORDER Before the Court is the motion of Defendants Nyxoah, Inc. and Nyxoah SA (collectively, “Nyxoah”) to disqualify the law firm Latham & Watkins LLP (“Latham”) from representing Plaintiff Inspire Medical Systems, Inc. (“Inspire”) in this case. (D.I. 11). For the reasons set forth below, Nyxoah’s motion to disqualify is GRANTED. I. BACKGROUND The relevant facts are largely not in dispute. (D.I. 21 at 1). Inspire is the creator of the Inspire system, a neurostimulation implant to treat sleep apnea. (D.I. 1 20-30). Nyxoah sought to introduce its own sleep-apnea implant device, Genio, to the market to compete with Inspire. (D.I. 12 at 1). In 2021, Nyxoah pursued an initial public offering (“IPO”) of stock in the United States to finance the development of Genio. (/d.). In connection with that process, Nyxoah retained Cantor Fitzgerald, L.P. (“Cantor Fitzgerald”), a financial services firm, to underwrite the IPO, and Cantor Fitzgerald was represented by Latham in the process. (/d. at 3). As is customary in underwriting, Cantor Fitzgerald conducted due diligence to determine the proper scope of representations that Nyxoah could make to the public under the Securities and Exchange Act. During that due diligence, Latham reviewed Nyxoah’s financial documents, as well as Nyxoah’s

internal documents discussing its Genio product and the scope of its intellectual property rights — and the scope of the rights of competitors, including Inspire. (/d. at 3-4). Nyxoah’s initial IPO closed on July 7, 2021. (DI. 12 at 3). Nyxoah subsequently had three additional stock offerings underwritten by Cantor Fitzgerald. (/d. at 4-5). Each time, Cantor Fitzgerald was represented by Latham. (D.I. 13 Jf 17, 25 & 32). And each stock offering was preceded by similar due diligence, all of which resulted in updated disclosures of the information provided with the initial offering. (/d. Jf 19, 27, 33 & 34). . In early 2025, Morgan Stanley, another financial services firm, agreed to underwrite another of Nyxoah’s proposed follow-on offerings. (D.I. 12 at 6). Latham also represented Morgan Stanley in the underwriting agreement with Nyxoah. (/d. at 6-7). Morgan Stanley also conducted due diligence in connection with the follow-on stock offering, which was largely the same as Cantor Fitzgerald’s due diligence. (/d. at 7). Before the 2025 stock offering, however, Latham withdrew from representing Morgan Stanley and Cantor Fitzgerald (“the Underwriters”) because of a “business conflict.” (D.I. 12 at 7; D.I. 21 at 12). That business conflict was ultimately revealed to be Latham’s representation of Inspire in the present case, where Inspire alleges that Nyxoah’s Genio infringes U.S. Patent Nos. 10,898,709, 11,806,526 and 11,850,424 (“the Asserted Patents”). (D.I. 12 at 7-8; D.I. 21 at 12; see also D.I. 1 J 84-119). When the full scope of this “business conflict” became apparent to Nyxoah, Nyxoah requested that Latham voluntarily withdraw from representing Inspire in this case. (D.I. 12 at 8; D.I. 14, Ex. 1). Latham refused, opting instead to implement an “ethical screen.” (D.J. 14, Ex. 2), Nyxoah then filed the pending motion (D.I. 11; see alse D.I. 12, 13 & 14), and briefing on the motion was complete on September 5, 2025 (D.I. 21, 22, 23 & 26).

II. LEGAL STANDARD A court has the inherent power to disqualify an attorney from a representation. See United States v. Miller, 624 F.2d 1198, 1201 (3d Cir. 1980). But motions to disqualify are “generally disfavored.” Talecris Biotherapeutics, Inc. v. Baxter Int'l Inc., 491 F. Supp. 2d 510, 513 (D. Del. 2007). The party seeking disqualification must clearly show that “continued representation would be impermissible” for a court to disqualify opposing counsel. Jd Determining whether representation is impermissible requires the Court to “carefully sift all the facts and circumstances.” Nemours Found. v. Gilbane, Aetna, Fed. Ins. Co., 632 F. Supp. 418, 428 (D. Del. 1986). If there are only “[vjague and unsupported allegations,” then the standard for disqualification is not met. Conley v. Chaffinch, 431 F. Supp. 2d 494, 496 (D. Del. 2006). Attorney conduct in the District of Delaware is primarily governed by the Model Rules of Professional Conduct (“the Model Rules” or “M.R.P.C.”). D. DEL. L.R. 83.6(d); see In re Corn Derivatives Antitrust Litig., 748 F.2d 157, 160 (3d Cir. 1984). When determining whether a conflict of interest exists among clients, there are two relevant rules: Model Rule 1.7, which involves conflicts between current clients, and Model Rule 1.9, which involves conflicts between a current and former client. See M.R.P.C. 1.7 & 1.9. Moreover, because of the importance in maintaining the public’s confidence in the bar, a court may disqualify an attorney “for failing to avoid even the appearance of impropriety.” Kabi Pharmacia AB v. Alcon Surgical, Inc., 803 F. Supp. 957, 960 (D. Del. 1992). In these circumstances, a court may disqualify an attorney even if there is no violation of the Model Rules, instead relying on the court’s inherent authority to supervise attorney conduct. See Intell. Ventures I LLC. v. Checkpoint Software Techs. Lid., C.A. No. 10-1067-LPS, 2011 WL 2692968, at *13 n.10 (D. Del. June 22, 2011); see also In re Grand Jury Investigation, 447 F. Supp. 2d 453, 458 (E.D. Pa. 2006) (“[D]isqualification need not be predicated upon the violation of any specific rule.”).

III. DISCUSSION Both sides agree that Latham never had an attorney-client relationship with Nyxoah. (D.I. 21 at 3-4; D.I. 26 at 1). Although not raised by either side, the Court first addresses whether Nyxoah has standing to seek disqualification here despite never having any sort of fiduciary or attorney-client relationship with Latham. Courts disagree on whether a non-client litigant has standing to bring a motion to disqualify. See Santander Sec. LLC v. Gamache, Civ. No. 17-317, 2017 WL 1208066, at *3-5 (E.D. Pa. Apr. 3, 2017) (summarizing split of authority). The Third Circuit has not squarely addressed the issue, first “assuming without deciding” that only a former client may raise disqualification, In re Corn Derivatives, 748 F.2d at 161, and then later “assuming without deciding” that non-clients may raise issues of disqualification, Jn re Pressman-Gutman Co., 459 F.3d 383, 401 n.20 (3d Cir. 2006). The Court finds persuasive the reasoning of the First, Fourth and Fifth Circuits, which allow non-clients to bring motions to disqualify counsel. See Kevlik v. Goldstein, 724 F.2d 844, 847-48 (1st Cir. 1984); United States v. Clarkson, 567 F.2d 270, 271 n.1 (4th Cir. 1977); Brown & Williamson Tobacco Corp. y. Daniel Int'l Corp., 563 F.2d 671, 673 (Sth Cir. 1977). Where, as here, a non-client faces a strategic disadvantage because its confidential information was accessed by opposing counsel and that information is highly relevant to the litigation at hand, the non-client has a sufficient personal stake in seeking disqualification such that standing exists. Cf Intell.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Robert Barnwell Clarkson
567 F.2d 270 (Fourth Circuit, 1977)
United States v. Miller, William G.
624 F.2d 1198 (Third Circuit, 1980)
United States v. Stout
723 F. Supp. 297 (E.D. Pennsylvania, 1989)
Kabi Pharmacia AB v. Alcon Surgical, Inc.
803 F. Supp. 957 (D. Delaware, 1992)
Strasbourger Pearson Tulcin Wolff Inc. v. Wiz Technology, Inc.
82 Cal. Rptr. 2d 326 (California Court of Appeal, 1999)
Conley v. Chaffinch
431 F. Supp. 2d 494 (D. Delaware, 2006)
Apeldyn Corporation v. Samsung Electronics Co., Ltd.
693 F. Supp. 2d 399 (D. Delaware, 2010)
Boston Scientific Corp. v. Johnson & Johnson Inc.
647 F. Supp. 2d 369 (D. Delaware, 2009)
Blue Planet Software, Inc. v. Games International, LLC
331 F. Supp. 2d 273 (S.D. New York, 2004)
Lowe v. Experian
328 F. Supp. 2d 1122 (D. Kansas, 2004)
In Re Grand Jury Investigation
447 F. Supp. 2d 453 (E.D. Pennsylvania, 2006)
HF Management Services LLC v. Pistone
34 A.D.3d 82 (Appellate Division of the Supreme Court of New York, 2006)
Cordy v. Sherwin-Williams Co.
156 F.R.D. 575 (D. New Jersey, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
Inspire Medical Systems, Inc. v. Nyxoah, Inc. and Nyxoah SA, Counsel Stack Legal Research, https://law.counselstack.com/opinion/inspire-medical-systems-inc-v-nyxoah-inc-and-nyxoah-sa-ded-2025.